

5 February 2018 14:00 GMT

**TRANSACTION BY PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES**  
**Disclosure under Article 19 of the EU Market Abuse Regulation**

AstraZeneca PLC (the Company) announces that, on 2 February 2018, it was notified by Philip Broadley, a Non-Executive Director of the Company, that, on 2 February 2018, Mr Broadley purchased 415 Ordinary Shares of \$0.25 each in the Company (Shares) at a price of 4846.3645 pence per Share.

The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, give further detail.

<b>1</b>	<b>Details of the person discharging managerial responsibilities / person closely associated</b>					
a)	Name	Philip Broadley				
<b>2</b>	<b>Reason for the notification</b>					
a)	Position/status	Non-Executive Director				
b)	Initial notification /Amendment	Initial notification				
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>					
a)	Name	AstraZeneca PLC				
b)	LEI	PY6ZZQWO2IZFZC3IOL08				
<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>					
a)	Description of the financial instrument, type of instrument  Identification code	Ordinary Shares of US\$0.25 each in AstraZeneca PLC  GB0009895292				
b)	Nature of the transaction	Share purchase				
c)	Price(s) and volume(s)	<table border="1"><tr><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>4846.3645 pence</td><td>415</td></tr></table>	Price(s)	Volume(s)	4846.3645 pence	415
Price(s)	Volume(s)					
4846.3645 pence	415					

d)	Aggregated information  - Aggregated volume  - Price	Not applicable - single transaction
e)	Date of the transaction	2 February 2018
f)	Place of the transaction	XLON

### About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit [www.astazeneca.com](http://www.astazeneca.com) and follow us on Twitter @AstraZeneca.

### Media Relations

Esra Erkal-Paler	UK/Global	+44 203 749 5638
Karen Birmingham	UK/Global	+44 203 749 5634
Rob Skelding	UK/Global	+44 203 749 5821
Matt Kent	UK/Global	+44 203 749 5906
Gonzalo Viña	UK/Global	+44 203 749 5916
Jacob Lund	Sweden	+46 8 553 260 20
Michele Meixell	US	+1 302 885 2677

### Investor Relations

Thomas Kudsk Larsen		+44 203 749 5712
Craig Marks	Finance, Fixed Income, M&A	+44 7881 615 764
Henry Wheeler	Oncology	+44 203 749 5797
Mitchell Chan	Oncology; Other	+1 240 477 3771
Christer Gruvris	Brilinta; Diabetes	+44 203 749 5711
Nick Stone	Respiratory; Renal	+44 203 749 5716

US toll free

+1 866 381 7277

**Adrian Kemp**  
**Company Secretary**  
**AstraZeneca PLC**